The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.
Authors
Dienstmann, Rodrigo
Rachid, Maan Haj
Boekel, Jorrit
Jonsson, Markus
Razzak, Ali
Braña, Irene
De Petris, Luigi
Yachnin, Jeffrey
Loriot, Yohann
Massard, Christophe
Martin-Romano, Patricia
Opdam, Frans
Schlenk, Richard F
Vernieri, Claudio
Masucci, Michele
Villalobos, Xenia
Chavarria, Elena
Cancer Core Europe consortium
Apolone, Giovanni
Garralda, Elena
Karlsson, Claes
Rodon, Jordi
Publication Date
2022-02Journal Title
Nat Cancer
ISSN
2662-1347
Publisher
Springer Science and Business Media LLC
Volume
3
Issue
2
Pages
251-261
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Tamborero, D., Dienstmann, R., Rachid, M. H., Boekel, J., Lopez-Fernandez, A., Jonsson, M., Razzak, A., et al. (2022). The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.. Nat Cancer, 3 (2), 251-261. https://doi.org/10.1038/s43018-022-00332-x
Abstract
There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical decision support system developed under the umbrella of Cancer Core Europe that creates a unified legal, scientific and technological platform to share and harness next-generation sequencing data. Automating the interpretation and reporting of sequencing results decrease the need for time-consuming manual procedures that are prone to errors. The adoption of an expert-agreed process to systematically link tumor molecular profiles with clinical actions promotes consistent decision-making and structured data capture across the connected centers. The use of information-rich patient reports with interactive content facilitates collaborative discussion of complex cases during virtual molecular tumor board meetings. Overall, streamlined digital systems like the MTBP are crucial to better address the challenges brought by precision oncology and accelerate the use of emerging biomarkers.
Keywords
Technical Report, /692/4028/67/69, /692/4028/67/68, /692/699/67, /631/114, technical-report
Sponsorship
European Commission Horizon 2020 (H2020) ERC (965397)
Medical Research Council (MR/P012442/1)
Identifiers
s43018-022-00332-x, 332
External DOI: https://doi.org/10.1038/s43018-022-00332-x
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334509
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.